NCT07302425 High-intensity Resistance Training in Post-exacerbation COPD
| NCT ID | NCT07302425 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituti Clinici Scientifici Maugeri SpA |
| Condition | COPD Exacerbation |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 64 participants in total. It began in 2025-10-30 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
After a COPD exacerbation, many individuals experience severe weakness in the leg muscles, especially the quadriceps. This weakness can make daily activities difficult and slow down recovery. Traditional respiratory rehabilitation usually focuses on endurance training, which is effective but often hard to tolerate soon after an exacerbation due to persistent symptoms and limited functional capacity. This study aims to compare two early rehabilitation approaches during recovery from a COPD exacerbation: a maximal strength training (MST) programme using high loads and few repetitions, and a traditional endurance-based training programme. The investigators aim to determine whether MST is easier to tolerate, especially in terms of breathlessness, and whether MST can improve muscle strength, efficiency, and overall exercise tolerance as well as or better than endurance training. The results will help identify the most suitable rehabilitation strategy for individuals recovering from a COPD exacerbation, particularly for those who struggle with high-intensity endurance exercise.
Eligibility Criteria
Inclusion Criteria: * COPD diagnosis according to the GOLD guidelines \[11\] with FEV1/FVC \<70% * Stable clinical condition (pH\>7.30) \[11\] * Hospital discharge within 3 weeks from an event of hospitalization due to an acute exacerbation of COPD. * Absence of significant motor disability, described by the possibility of performing the 6MWT. Exclusion Criteria: * Presence of lung diseases other than COPD * Orthopedic and neurological conditions that prevent the execution of functional tests * Severe neurological and cardiologic comorbidities or other severe diseases compromise exercise tolerance. * Cognitive impairment evaluated by Mini-Mental State Examination (MMSE) score as \< 25.
Contact & Investigator
Mara Paneroni, PhD, MSc
STUDY DIRECTOR
ICS Maugeri IRCCS, respiratory rehabilitation of the Institute of Lumezzane
Frequently Asked Questions
Who can join the NCT07302425 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COPD Exacerbation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07302425 currently recruiting?
Yes, NCT07302425 is actively recruiting participants. Contact the research team at mara.paneroni@icsmaugeri.it for enrollment information.
Where is the NCT07302425 trial being conducted?
This trial is being conducted at Lumezzane, Italy.
Who is sponsoring the NCT07302425 clinical trial?
NCT07302425 is sponsored by Istituti Clinici Scientifici Maugeri SpA. The principal investigator is Mara Paneroni, PhD, MSc at ICS Maugeri IRCCS, respiratory rehabilitation of the Institute of Lumezzane. The trial plans to enroll 64 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.